Panidis, Dimitrios (57198332153)Dimitrios (57198332153)PanidisTziomalos, Konstantinos (6603555093)Konstantinos (6603555093)TziomalosMacUt, Djuro (35557111400)Djuro (35557111400)MacUtDelkos, Dimitrios (22979221400)Dimitrios (22979221400)DelkosBetsas, George (25621272300)George (25621272300)BetsasMisichronis, Georgios (54179645100)Georgios (54179645100)MisichronisKatsikis, Ilias (8696325300)Ilias (8696325300)Katsikis2025-06-122025-06-122012https://doi.org/10.1016/j.fertnstert.2011.11.041https://www.scopus.com/inward/record.uri?eid=2-s2.0-84856383958&doi=10.1016%2fj.fertnstert.2011.11.041&partnerID=40&md5=97488b4003655f4f4641b13242623463https://remedy.med.bg.ac.rs/handle/123456789/9777Objective: To assess the effects of age on the hormonal, metabolic, and ultrasonographic features of polycystic ovary syndrome (PCOS). Design: Observational study. Setting: University department of obstetrics and gynecology. Patient(s): Patients with PCOS (n = 1,212) and healthy women (n = 254). Intervention(s): None. Main Outcome Measure(s): Differences in the hormonal, metabolic, and ultrasonographic features of PCOS between age groups. Result(s): A progressive decline in circulating androgens was observed with advancing age. Patients 21-30 years old had lower plasma glucose and insulin levels, lower area under the oral glucose tolerance test curve and lower homeostasis model assessment of insulin resistance index, and higher glucose/insulin and quantitative insulin sensitivity check index than patients 31-39 years old. The prevalence of PCOS phenotypes changed with age. More specifically, the distribution of the phenotypes did not differ substantially between patients ≤20 years old and patients 21-30 years old. However, a decline in the prevalence of phenotype 1 (characterized by anovulation, hyperandrogenemia, and polycystic ovaries) and an increase in the prevalence of phenotype 4 (characterized by anovulation and polycystic ovaries without hyperandrogenemia) were observed in patients 31-39 years old. Conclusion(s): In women with PCOS, hyperandrogenemia appears to diminish during reproductive life whereas insulin resistance worsens. © 2012 American Society for Reproductive Medicine, Published by Elsevier Inc.agehyperandrogenemiainsulin resistancePolycystic ovary syndromepolycystic ovary syndrome phenotypes